By the end of 2033, the chronic idiopathic constipation treatment market is expected to have grown from a projected value of US$ 9.4 billion in 2023 to US$ 19.7 billion, expanding quickly at a CAGR of 7.5%. When a person has difficult, infrequent, and/or suboptimal defecation, it is known as chronic idiopathic constipation (CIC), a common functional bowel disorder. Chronic idiopathic constipation is becoming more common due to factors like sedentary lifestyles, growing anti-inflammatory medicine use, and a rapid decline in dietary fibre consumption. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=8517 Additionally, rising rate of the ageing population, sedentary lifestyles, and dietary changes are contributing to the increasing burden of CIC, thereby driving the demand for treatment options. Fiber supplements, laxatives, stool softeners, and prokinetic agents are commonly used as medications in the management of CIC. Furthermore, advancements in digital health technologies are also shaping the future of chronic idiopathic constipation treatment. Mobile applications, wearable devices, and remote monitoring tools are being developed to help patients track their bowel movements, diet, and exercise habits, and provide personalized recommendations for managing CIC. Key Highlights Worldwide sales of chronic idiopathic constipation drugs are expected to reach US$ 19.7 billion by 2033. The United States market is expanding rapidly due to the presence of key market players. Rising prevalence of chronic idiopathic constipation among the older population in Japan is boosting the demand for chronic idiopathic constipation treatment procedures. Germany is expected to be a lucrative market for manufacturers of chronic idiopathic constipation drugs due to the existence of advanced healthcare systems. “Key market players are striving to introduce cutting-edge solutions that can provide effective and safe relief for chronic idiopathic constipation patients,” says a Fact.MR analyst. Competitive Landscape According to Fact.MR, a market research and competitive intelligence provider, key players in the chronic idiopathic constipation treatment market are focused on developing technologically advanced solutions, introducing new design products, obtaining regulatory clearances, and partnering and acquiring other businesses. The FDA approval for newly discovered medications is currently being sought by leading companies in the chronic idiopathic constipation treatment market. Over the forecast period, obtaining FDA approval is anticipated to continue to be one of the primary areas of attention for the producers of medications for chronic idiopathic constipation. The FDA has just given the all-clear to several medications. An osmotic laxative created by Braintree Laboratories (Sebela) was given FDA approval in February 2020 to treat adults with chronic idiopathic constipation. Ironwood Pharmaceuticals, Inc. reported in April 2020 that the USPTO has granted certificates of approval for patent applications relating to the formulation of the 72 mcg dose of LINZESS. The U.S. Food and Drug Administration granted Sebela Pharmaceuticals, Inc. permission to market Pizensy (lactitol) in March 2020. Chronic idiopathic constipation treatment market forecast by Fact.MR Recent Market Developments In Japan, the effective chronic constipation medication ‘Movicol HD’ was introduced in May 2022 by EA Pharma and Mochida Pharmaceutical. The United States Food and Drug Administration (USFDA) approved Ibsrela a medication produced by Ardelyx, Inc. in April 2022. This NHE3 inhibitor is used to treat adult patients with IBS-C (irritable bowel syndrome with constipation). Industry Research By Type: Normal-transit Constipation Slow-transit Constipation By Therapy: Pharmacological Therapies Non-pharmacological Therapies By Treatment: Medication Surgery By Drug: Serotonin-4 (5-Ht4) Receptor Agonist Guanylate Cyclase-C Agonist Laxatives Stimulants By Route of Administration: Oral Injectable By End User: Hospitals Homecare Specialty Clinics By Region: North America Latin America Europe East Asia South Asia & Oceania MEA Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=8517
Last changed by  
 
Factmrsurvey
35

Read more

Untitled

The Automotive Ceramics Industry sales study offers a comprehensive analysis on diverse features including production capacities, Automotive Ceramics demand, product developments, sales revenue generation and Automotive Ceramics market outlook across the globe. 170 page market research report by Fact.MR, (Leading business and competitive intelligence provider) on global Automotive Ceramics market sales initiates with an outlook of the market, followed by the scrutiny of the demand and consumption volumes and share and size of various end-use segments The global automotive ceramics market was valued at US$ 2.3 Billion in 2021 and market is valued at US$ 2.42 Billion in 2022 During the 2022-2032 period of assessment, demand is expected to rise at a 5.4% value CAGR, likely to reach US$ 6.6 Billion by the end of the said forecast period. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=6406 The readability score of the Automotive Ceramics market demand report is good as it offers chapter-wise layout with each section divided into a smaller sections.

8/7/2023
Preimplantation Genetic Testing Market to Hit Valuation of US$ 1,420 Million by 2032

Through 2032, the preimplantation genetic testing market is anticipated to develop at a CAGR of around 9% and reach a significant market size. Growth opportunities are expanding as a result of the rising prevalence of genetic illnesses. The market is anticipated to reach US$ 653.52 million by 2022 and will continue to grow, reaching US$ 1,420 million by 2032. Download Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=292 The biggest benefit offered by preimplantation testing is it offers an opportunity to conceive a pregnancy unaffected by genetic conditions. Researchers and healthcare institutes are trying to find new methods and techniques using the latest technology to minimize various risks associated with preimplantation genetic testing. Key Highlights

8/7/2023
Global Implantable Medical Devices Market Is Predicted To Reach US$ 155 Billion By 2027

According to Fact.MR’s most recent industry analysis, implanted medical device market sales are expected to grow globally between 2022 and 2027 at a compound annual growth rate of 6.1%. The market for implantable medical devices is expanding as a result of increased chronic illness prevalence, an ageing population, and improvements in active implanted medical devices. Additionally, increased funding and investments in the creation of technologically advanced products, elevated awareness of advancements in medical implants, and an increase in the use of neurostimulators are all contributing to market expansion. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7728 Incidence of cardiovascular diseases is rising, and obesity rates are high, which are the main drivers that are likely to fuel market growth for implantable medical devices. Medical professionals and patients can monitor their illnesses to receive an early update with the use of implantable medical devices. These wireless, automated devices assess a patient’s sensitivity to a prescribed medicine dosage. The rising prevalence of neurological illnesses such as Parkinson’s disease and spasticity is driving the demand for active implantable medical devices.

8/7/2023
Worldwide Shipments of Anesthesia Monitoring Devices are Anticipated to Increase at an Impressive CAGR of 9.1% by 2032

Anaesthesia monitoring equipment market sales are anticipated to grow globally between 2022 and 2027 at a strong CAGR of 9.1%. The market for anaesthesia monitoring devices is currently worth US$ 2.2 billion. Since there has been a noticeable rise in the prevalence of chronic diseases, more surgeries are being conducted, which increases the demand for anaesthesia apparatus, including anaesthesia monitoring devices. A growing elderly population, rising healthcare costs, and product technology developments are further variables that may boost demand for anaesthesia monitoring devices. The expensive cost of anaesthesia monitoring equipment, however, is anticipated to limit market potential to some degree. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7683 Anesthesia monitoring device manufacturing companies are focusing on the expansion of their product portfolios and are also expanding their business scope by gaining new approvals from regulatory authorities. In April 2022, GE Healthcare, a leading name in the medical industry, announced that it had received pre-market approval from the U.S. FDA for its new software to deliver general anesthesia. The End-Tidal (Et) Control software is cleared to be used on GE’s Aisys CS2 Anesthesia Delivery System.

8/7/2023
Read more from Factmrsurvey
Published on HackMD